Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.
Your search for bevacizumab returned 4 results
There was no improvement in overall survival with bevacizumab.
Researchers investigated the association between nonalcoholic fatty liver disease and early-onset colorectal cancer according to anatomical site.
The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.